SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Human Genome Sciences, Inc. (HGSI) -- Ignore unavailable to you. Want to Upgrade?


To: Brian1970 who wrote (347)11/18/1999 7:58:00 PM
From: David Bogdanoff  Read Replies (1) | Respond to of 1127
 
To all;

HGSI has had several advantages over many other worthy biotechs; in particular it is known and followed by major analysts and is large enough to attract investments from funds. Of course it has a promising, if risky, business strategy helps too; it is aiming to become a complete pharmaceutical company and market its own drugs, not just remain a research biotech company.

David